share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

SEC announcement ·  Aug 2 05:41
Summary by Futu AI
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.